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AUTHOR SUMMARY
ABSTRACT
Background.Vascular endothelial growth factor (VEGF) and
VEGFreceptor2(VEGFR-2)arebelievedtomediateangiogenesis
in colorectal cancer (CRC). Ramucirumab (RAM; IMC-1121B) is
a human IgG1 monoclonal antibody that inhibits VEGF ligand
binding toVEGFR-2, inhibitingVEGFR-2 activationand signaling.
Methods. Patients with metastatic CRC, Eastern Cooperative
Oncology Group performance status 0–1, and adequate organ
function who had not received chemotherapy for metastatic
disease received RAM and the modified FOLFOX-6 regimen
every 2 weeks. Endpoints included progression-free survival
(PFS), objective response rate, overall survival, and safety.The
sample size was based on a potentially improved median PFS
from 8 months to 11 months.
Results. Forty-eight patients received therapy. Median PFSwas
11.5 months (95% confidence interval [CI]: 8.6–13.1 months).
The objective response rate was 58.3% (95% CI: 43.21–72.39).
The disease control rate (complete or partial response plus
stable disease) was 93.8% (95% CI: 82.8–98.7). Median overall
survival was 20.4months (95%CI: 18.5–25.1months).Themost
frequent grade3–4adverse events includedneutropenia (grade
3: 33.3%; grade 4: 8.3%), hypertension (grade 3: 16.7%), and
neuropathy (grade3: 12.5%).Twopatients diedduring the study
due to myocardial infarction and cardiopulmonary arrest.
Conclusion. RAM may enhance the efficacy of modified
FOLFOX-6 chemotherapy with an acceptable safety profile in
metastatic CRC. The Oncologist 2014;19:350–351
DISCUSSION
The combination of ramucirumab (RAM) and the modified
FOLFOX-6 regimen (mFOLFOX-6) appears efficacious in the
first-line treatment of patients with metastatic colorectal
cancer (mCRC).Themedianprogression-free survival (PFS) of
11.5 months (Fig. 1), an objective response rate of 58.3%,
a disease control rate of 93.8% (stable disease defined as
neither shrinkagesufficient toqualify for partial responsenor
increase sufficient to qualify for progressive disease, taking
as a reference the smallest sum longest diameter since the
Figure 1. Progression-free survival curve: Kaplan-Meier plot for
progression-free survival for all patients.
Abbreviations: CI, confidence interval; mFOLFOX-6, modified
FOLFOX-6 regimen; PFS, progression-free survival.
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start of treatment), and median overall survival (OS) of 20.4
months are encouraging and suggest that RAMmay enhance
the efficacy of mFOLFOX-6 in mCRC. Figure 2 shows that the
majority of the study population experienced some tumor
burden reduction, including patients with liver-only disease
and those with more extensive patterns of metastases.
Although many patients discontinued oxaliplatin after 5–8
months of therapy, 23% continued to receive RAM and
5-fluorouracil with ongoing disease control for more than
5months after discontinuation of oxaliplatin.Themedian OS
was 20.4 months.
The incidence ofmost adverse events in patients receiving
RAM and mFOLFOX-6 was consistent with the known adverse
event profile of mFOLFOX-6 in mCRC [1–6]. Hypertension
(including 16.7% at grade 3 and no grade 4) and proteinuria
(12.5% at grade 2 and one grade 4 nephrotic syndrome) were
observed. Two patients experienced grade 5 potential arterial
thromboembolic events (myocardial infarction and cardiopul-
monary arrest), and three patients had grade 3–4 venous
thromboembolic events (pulmonary embolism, deep vein
thrombosis, jugular vein thrombosis).
Exploratory pharmacokinetic, pharmacodynamic, and
correlative analyses were conducted in samples collected
from nine patients. Mean trough levels after repeated dosing
of 8 mg/kg of RAM every 2 weeks exceeded concentrations
associatedwithantitumoractivity inpreclinicalmodels.Higher
baseline levels of soluble Flt-1 (soluble VEGFR-1) and VEGF-A
and lower baseline levels of VEGF-D appeared tobe associated
with longer PFS and OS. Because this was a single-arm trial, no
conclusions can be drawn regarding whether these potential
associations are prognostic or predictive. Conclusions are
also limited by the sample size and should be considered
hypothesis generating.
Inconclusion,RAMmayenhance theefficacyofmFOLFOX-6
in mCRC. The overall adverse event profile of the combination
appears to be largely consistent with the toxicity profile of the
constituent chemotherapeutic agents and the known safety
profile of RAM to date. However, the modest sample size
and the single-arm design of the study preclude definitive
assessment regarding these conclusions.
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Figure 2. Waterfall plot of best percentage change frombaseline
in size of target tumor lesions. Best change in target-lesion size is
maximum reduction from baseline or minimum increase in
absence of reduction.
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